Skip to main content
SpringerLink
Log in

Retroperitoneal Lymph Node Dissection

  • Chapter
  • First Online:
A Guide to Management of Urological Cancers

  • 185 Accesses

Abstract

Retroperitoneal lymph node dissection remains an integral part of the management of germ cell tumours. The advent of highly effective cisplatin-based chemotherapy, information about primary lymphatic landing zones and the need to preserve the post-sympathetic ganglionic fibres for the preservation of ejaculatory function has changed the way RPLND is performed and utilised in the management of GCT (germ cell tumour). In this chapter, we review the role of RPLND in the management of germ cell tumours as well as the relevant anatomy and surgical techniques along with their outcomes and complications in the modern era.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20.

    Article  CAS  PubMed  Google Scholar 

  2. Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol. 1987;138(1):77–82.

    Article  CAS  PubMed  Google Scholar 

  3. Ray B, Hajdu SI, Whitmore WF Jr. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974;33(2):340–8.

    Article  CAS  PubMed  Google Scholar 

  4. Katz MH, Eggener SE. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009;27(4):477–83.

    Article  PubMed  Google Scholar 

  5. Hiester A, Nini A, Fingerhut A, Große Siemer R, Winter C, Albers P, et al. Preservation of ejaculatory function after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testicular cancer: template vs. bilateral resection. Front Surg. 2019;5:80.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Doerr A, Skinner EC, Skinner DG. Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol. 1993;149(6):1472–4.

    Article  CAS  PubMed  Google Scholar 

  7. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007;25(28):4365–9.

    Article  PubMed  Google Scholar 

  8. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld JJ. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007;177(3):937–43.

    Article  PubMed  Google Scholar 

  9. Beveridge TS, Allman BL, Johnson M, Power A, Sheinfeld J, Power NE. Retroperitoneal lymph node dissection: anatomical and technical considerations from a cadaveric study. J Urol. 2016;196(6):1764–71.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Speir RW, Cary C, Masterson TA. Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes. Transl Androl Urol. 2020;9(Suppl 1):S83.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Albers P, Nini A, Hiester A, Winter C, Lusch A, Lorch A. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting. Eur Urol. 2019;37(7_Suppl):524.

    Google Scholar 

  12. Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology. 1997;50(6):957–62.

    Article  CAS  PubMed  Google Scholar 

  13. Pedrosa JA, Masterson TA, Rice KR, Bihrle R, Beck SD, Foster RS. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival. J Urol. 2014;191(6):1777–82.

    Article  PubMed  Google Scholar 

  14. Murphy AM, McKiernan JM. Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol. 2009;27(4):501–6.

    Article  PubMed  Google Scholar 

  15. Syan-Bhanvadia S, Bazargani ST, Clifford TG, Cai J, Miranda G, Daneshmand S. Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity. Eur Urol. 2017;72(5):814–20.

    Article  PubMed  Google Scholar 

  16. Kim P, Syan-Bhanvadia S, Djaladat H, Faber K, Tadros NN, Nichols C, et al. Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor. Urology. 2012;80(4):941–5.

    Article  PubMed  Google Scholar 

  17. Hillelsohn JH, Duty BD, Okhunov Z, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for testicular cancer. Arab J Urol. 2012;10(1):66–73.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Shishido T, Okegawa T, Hayashi K, Masuda K, Taguchi S, Nakamura Y, et al. Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: a comparison of clinical and perioperative outcomes. Asian J Urol. 2022;9(2):119–24.

    Article  PubMed  Google Scholar 

  19. Heidenreich A, Albers P, Hartmann M, Kliesch S, KÖHrmann K-U, Krege S, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I Nonseminomatous germ cell tumors of the testis: experience of the German testicular cancer study group. J Urol. 2003;169(5):1710–4.

    Article  PubMed  Google Scholar 

  20. Heidenreich A, Paffenholz P, Nestler T, Pfister DJ. Primary and postchemotherapy retroperitoneal lymphadenectomy for testicular cancer. Oncol Res Treat. 2018;41(6):370–8.

    Article  CAS  PubMed  Google Scholar 

  21. Cary KC, Beck SD, Bihrle R, Foster RS. Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;189(3):812–7.

    Article  PubMed  Google Scholar 

  22. Blok JM, Meijer RP, van der Poel HG, Bex A, van Vooren J, van Urk JJ, et al. Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals. World J Urol. 2021;39(3):839–46.

    Article  PubMed  Google Scholar 

  23. Stephenson AJ, Tal R, Sheinfeld JJ. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176(5):1996–9.

    Article  PubMed  Google Scholar 

  24. Macleod LC, Rajanahally S, Nayak JG, Parent BA, Ramos JD, Schade GR, et al. Characterizing the morbidity of postchemotherapy retroperitoneal lymph node dissection for testis cancer in a national cohort of privately insured patients. Urology. 2016;91:70–6.

    Article  PubMed  Google Scholar 

  25. Djaladat H, Nichols C, Daneshmand SJ. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection. Ann Surg Oncol. 2012;19(7):2388–93.

    Article  PubMed  Google Scholar 

  26. Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister DJ. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol. 2017;28(2):362–7.

    Article  CAS  PubMed  Google Scholar 

  27. Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61(2):403–9.

    Article  PubMed  Google Scholar 

  28. Johnston P, Beck SD, Cheng L, Masterson TA, Bihrle R, Kesler K, et al. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;190(3):874–7.

    Article  PubMed  Google Scholar 

  29. Sheinfeld JJ. Risks of the uncontrolled retroperitoneum. Ann Surg Oncol. 2003;10(2):100.

    Article  PubMed  Google Scholar 

  30. Hartmann J, Candelaria M, Kuczyk M, Schmoll H-J, Bokemeyer CJ. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843–7.

    Article  CAS  PubMed  Google Scholar 

  31. Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol. 2001;19(10):2647–57.

    Article  CAS  PubMed  Google Scholar 

  32. Carver BS, Sheinfeld JJ. Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol. 2009;27(4):489–92.

    Article  PubMed  Google Scholar 

  33. Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012;79(1):156–9.

    Article  PubMed  Google Scholar 

  34. Jacobsen N-EB, Beck SD, Jacobson LE, Bihrle R, Einhorn LH, Foster RS. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol. 2010;184(3):949–53.

    Article  PubMed  Google Scholar 

  35. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008;26(34):5524.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94(6):1668–76.

    Article  PubMed  Google Scholar 

  37. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, et al. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007;110(12):2700–8.

    Article  PubMed  Google Scholar 

  38. Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006;176(1):100–4.

    Article  PubMed  Google Scholar 

  39. Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol. 2004;171(5):1835–8.

    Article  PubMed  Google Scholar 

  40. Donohue J, Leviovitch I, Foster R, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16(2):65–71.

    CAS  PubMed  Google Scholar 

  41. Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld JJ. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007;109(3):528–35.

    Article  PubMed  Google Scholar 

  42. Albers P, Ganz A, Hannig E, Miersch WD, Müller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164(2):381–4.

    Article  CAS  PubMed  Google Scholar 

  43. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23(25):6149–56.

    Article  PubMed  Google Scholar 

  44. Ong TA, Winkler MH, Savage PM, Seckl MJ, Christmas T. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU Int. 2008;102(2):198–202.

    Article  PubMed  Google Scholar 

  45. Baniel J, Foster R, Rowland R, Bihrle R, Donohue JJ. Testis cancer: complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153(3S):976–80.

    Article  CAS  PubMed  Google Scholar 

  46. Michael H, Lucia J, Foster RS, Ulbright TM. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol. 2000;24(2):257–73.

    Article  CAS  PubMed  Google Scholar 

  47. Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171(5):1839–41.

    Article  PubMed  Google Scholar 

  48. Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol. 2010;28(5):504–9.

    Article  PubMed  Google Scholar 

  49. Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: additional procedures and perioperative complications. Urol Oncol. 2015;33(9):389.e15–21.

    Article  PubMed  Google Scholar 

  50. Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HF, Glimelius I, et al. Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol. 2020;3(3):382–9.

    Article  PubMed  Google Scholar 

  51. Beck SDW, Peterson MD, Bihrle R, Donohue JP, Foster RS. Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary Group of Patients. J Urol. 2007;178(2):504–6.

    Article  PubMed  Google Scholar 

  52. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage a testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237–43.

    Article  CAS  PubMed  Google Scholar 

  53. Cary C, Foster RS, Masterson TA. Complications of retroperitoneal lymph node dissection. Urol Clin North Am. 2019;46(3):429–37.

    Article  PubMed  Google Scholar 

  54. Albers P, Lusch A, Che Y, Arsov C, Niegisch G, Hiester A. The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma. Eur Urol. 2022;40(6_Suppl):420.

    Google Scholar 

  55. Daneshmand S, Cary C, Masterson TA, Einhorn L, Boorjian SA, Kollmannsberger CK, et al. SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. Am Soc Clin Oncol. 2021;39:375.

    Article  Google Scholar 

  56. Leão R, van Agthoven T, Figueiredo A, Jewett MA, Fadaak K, Sweet J, et al. Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor. J Urol. 2018;200(1):126–35.

    Article  PubMed  Google Scholar 

  57. Kremer L, von Brandenstein M, Wittersheim M, Koeditz B, Paffenholz P, Hellmich M, et al. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens. Transl Androl Urol. 2021;10(4):1647–55.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Baessler B, Nestler T, Pinto dos Santos D, Paffenholz P, Zeuch V, Pfister D, et al. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Eur Radiol. 2020;30(4):2334–45.

    Article  PubMed  Google Scholar 

  59. Nestler T, Baeßler B, Santos DPD, Pfister DJKP, Maintz D, Heidenreich A. Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics. J Clin Oncol. 2019;37(7_Suppl):527.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology (Uro Oncology Unit), Homi Bhabha National Institute, Tata Memorial Centre, Tata Memorial Hospital, Mumbai, India

    Ajit Gujela & Gagan Prakash

Authors
  1. Ajit Gujela
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gagan Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Prabhjot Singh

  2. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Brusabhanu Nayak

  3. Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Sridhar Panaiyadiyan

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gujela, A., Prakash, G. (2023). Retroperitoneal Lymph Node Dissection. In: Singh, P., Nayak, B., Panaiyadiyan, S. (eds) A Guide to Management of Urological Cancers. Springer, Singapore. https://doi.org/10.1007/978-981-99-2341-0_26

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-2341-0_26

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-2340-3

  • Online ISBN: 978-981-99-2341-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation